- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Aurobindo Pharma shares rise nearly 7 percent after Q2 results
New Delhi: Shares of Aurobindo Pharma on Thursday gained nearly 7 percent in early trade after the company reported a 26 percent increase in consolidated net profit in the second quarter ended September.After opening in the green, the stock further jumped 6.47 percent to Rs 863.60 on the BSE.On the NSE, shares of the company rose by 6.56 percent to Rs 864.Aurobindo Pharma on Wednesday reported...
New Delhi: Shares of Aurobindo Pharma on Thursday gained nearly 7 percent in early trade after the company reported a 26 percent increase in consolidated net profit in the second quarter ended September.
After opening in the green, the stock further jumped 6.47 percent to Rs 863.60 on the BSE.
On the NSE, shares of the company rose by 6.56 percent to Rs 864.
Aurobindo Pharma on Wednesday reported a 26 percent increase in consolidated net profit at Rs 805.65 crore in the second quarter ended September.
The company had posted a consolidated net profit of Rs 639.53 crore in the same quarter last fiscal, Aurobindo Pharma said in a regulatory filing.
Consolidated total revenue from operations during the period under review stood at Rs 6,483.44 crore as against Rs 5,600.47 crore in the corresponding quarter last fiscal, it added.
Aurobindo Pharma Managing Director N Govindarajan said: "We continue to perform well across all our key geographies and segments to report a consistent set of earnings."
Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751